Zentalis Pharmaceuticals Appoints New CMO, Director
Ticker: ZNTL · Form: 8-K · Filed: Apr 11, 2024 · CIK: 1725160
Sentiment: neutral
Topics: executive-appointment, board-of-directors, personnel-change
Related Tickers: ZNTL
TL;DR
Zentalis names new CMO, adds director to board.
AI Summary
Zentalis Pharmaceuticals, Inc. announced on April 5, 2024, the appointment of Dr. Lori J. Rabin as Chief Medical Officer and the election of Ms. Karen L. Smith to its Board of Directors. The company also disclosed compensatory arrangements for its officers, details of which are filed as exhibits.
Why It Matters
Changes in key leadership roles and board composition can signal strategic shifts or governance updates for the company.
Risk Assessment
Risk Level: low — This filing primarily concerns executive appointments and board changes, which are routine corporate governance events.
Key Players & Entities
- Zentalis Pharmaceuticals, Inc. (company) — Registrant
- Dr. Lori J. Rabin (person) — Appointed Chief Medical Officer
- Ms. Karen L. Smith (person) — Elected to Board of Directors
- April 5, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new Chief Medical Officer?
Dr. Lori J. Rabin has been appointed as the Chief Medical Officer.
Who has been elected to the Board of Directors?
Ms. Karen L. Smith has been elected to the Board of Directors.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is April 5, 2024.
What other information is provided regarding officer compensation?
Compensatory arrangements of certain officers are disclosed, with details filed as exhibits.
What is the company's Central Index Key (CIK)?
The company's Central Index Key is 0001725160.
Filing Stats: 1,199 words · 5 min read · ~4 pages · Grade level 10.4 · Accepted 2024-04-11 07:00:55
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share ZNTL The Nasdaq Glo
Filing Documents
- zntl-20240405.htm (8-K) — 34KB
- 0001725160-24-000087.txt ( ) — 160KB
- zntl-20240405.xsd (EX-101.SCH) — 2KB
- zntl-20240405_lab.xml (EX-101.LAB) — 22KB
- zntl-20240405_pre.xml (EX-101.PRE) — 13KB
- zntl-20240405_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ZENTALIS PHARMACEUTICALS, INC. Date: April 11, 2024 By: /s/ Kimberly Blackwell, M.D. Kimberly Blackwell, M.D. Chief Executive Officer